{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:33:11Z","timestamp":1783625591208,"version":"3.55.0"},"reference-count":67,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>While recent improvements in survival for pediatric patients with newly diagnosed B-cell precursor acute lymphoblastic leukemia (B-ALL) have been attributed to risk stratification algorithms incorporating somatic genetics and early response dictating therapeutic intensity, recent antibody-based immunotherapeutic agents are changing the therapeutic landscape. Blinatumomab, inotuzumab ozogamicin, and chimeric antigen T-cell receptor therapies are approved by the US Food and Drug Administration for the treatment of relapsed and refractory B-ALL in children, and some have been incorporated into frontline therapies. Studies in both pediatric and adult patients have recently demonstrated superiority of adding blinatumomab to the consolidation phase of treatment in the frontline setting. Revisiting genomic classifiers of B-ALL in the era of antibody-based immunotherapeutic agents may be necessary to maximize the benefits of current risk stratification algorithms in combination with immunotherapy. Available data suggest the efficacy of these agents across genomic subtypes. Here we consider the impact of immunotherapeutic agents within the context of minimal residual disease and molecular classification\u2013based risk stratification.<\/jats:p>","DOI":"10.1182\/hematology.2025000712","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:08:12Z","timestamp":1764943692000},"page":"252-261","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Revisiting novel genomic classifiers in the era of immunotherapy for pediatric B-ALL"],"prefix":"10.1182","volume":"2025","author":[{"given":"Ruth W.","family":"Wang'ondu","sequence":"first","affiliation":[{"name":"1 Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mignon L.","family":"Loh","sequence":"additional","affiliation":[{"name":"2 Ben Towne Center for Childhood Cancer Research and the Department of Pediatrics, Seattle Children's Hospital, University of Washington, and the Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"35","key":"2025120616325978400_hem2025000712C1","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.19.01692","article-title":"Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16","volume":"37","author":"Jeha","year":"2019","journal-title":"J Clin Oncol"},{"issue":"36","key":"2025120616325978400_hem2025000712C2","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1200\/JCO.23.01286","article-title":"Advancing diagnostics and therapy to reach universal cure in childhood ALL","volume":"41","author":"Pieters","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025120616325978400_hem2025000712C3","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/s41375-023-01870-8","article-title":"Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932","volume":"37","author":"Schore","year":"2023","journal-title":"Leukemia"},{"issue":"21","key":"2025120616325978400_hem2025000712C4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood.V124.21.793.793","article-title":"Outstanding outcome for children with standard risk-low (SR-Low) acute lymphoblastic leukemia (ALL) and no benefit to intensified peg-asparaginase (PEG-ASNase) therapy: results of Children's Oncology Group (COG) Study AALL0331","volume":"124","author":"Mattano","year":"2014","journal-title":"Blood"},{"issue":"36","key":"2025120616325978400_hem2025000712C5","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1200\/JCO.22.00245","article-title":"Time to cure for childhood and young adult acute lymphoblastic leukemia is independent of early risk factors: long-term follow-up of the UKALL2003 trial","volume":"40","author":"Moorman","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"2025120616325978400_hem2025000712C6","doi-asserted-by":"crossref","first-page":"e30585","DOI":"10.1002\/pbc.30585","article-title":"Children's Oncology Group blueprint for research: acute lymphoblastic leukemia","volume":"70","author":"Raetz","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2025120616325978400_hem2025000712C7","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/s41375-019-0670-y","article-title":"Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial","volume":"34","author":"Attarbaschi","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"2025120616325978400_hem2025000712C8","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1200\/JCO.23.01388","article-title":"Four additional doses of PEG-L- asparaginase during the consolidation phase in the AIEOP-BFM ALL 2009 protocol do not improve outcome and increase toxicity in high-risk ALL: results of a randomized study","volume":"42","author":"Conter","year":"2024","journal-title":"J Clin Oncol"},{"issue":"15","key":"2025120616325978400_hem2025000712C9","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO-24-01851","article-title":"High-dose methotrexate in children and young adults with ALL and lymphoblastic lymphoma: results of the randomized phase III study UKALL 2011","volume":"43","author":"Kirkwood","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025120616325978400_hem2025000712C10","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(23)00088-1","article-title":"Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372\/COG AALL1122): a single-arm, multicentre, phase 2 trial","volume":"10","author":"Hunger","year":"2023","journal-title":"Lancet Haematol"},{"issue":"2","key":"2025120616325978400_hem2025000712C11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood.2024024936","article-title":"Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV\/XVI studies","volume":"145","author":"Purvis","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2025120616325978400_hem2025000712C12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2017.74.4946","article-title":"Reduced-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: results of an international randomized trial (AIEOP-BFM ALL 2000)","volume":"36","author":"Schrappe","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025120616325978400_hem2025000712C13","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41375-024-02287-7","article-title":"ETV6::RUNX1 acute lymphoblastic leukemia: how much therapy is needed for cure?","volume":"38","author":"\u00d8stergaard","year":"2024","journal-title":"Leukemia"},{"issue":"20","key":"2025120616325978400_hem2025000712C14","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.3390\/jcm10204728","article-title":"Curing the curable: managing low-risk acute lymphoblastic leukemia in resource limited countries","volume":"10","author":"Oh","year":"2021","journal-title":"J Clin Med"},{"issue":"8","key":"2025120616325978400_hem2025000712C15","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/leu.2009.42","article-title":"Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)\/TCF3-PBX1","volume":"23","author":"Jeha","year":"2009","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2025120616325978400_hem2025000712C16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2024-198507","article-title":"Prognostic Impact of t(1;19) in pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients treated on contemporary Children's Oncology Group (COG) Protocols","volume":"144","author":"Pinchinat","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2025120616325978400_hem2025000712C17","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"issue":"25","key":"2025120616325978400_hem2025000712C18","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children's Oncology Group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025120616325978400_hem2025000712C19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"2025120616325978400_hem2025000712C20","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"2025120616325978400_hem2025000712C21","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"2025120616325978400_hem2025000712C22","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"2025120616325978400_hem2025000712C23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2025120616325978400_hem2025000712C24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"2025120616325978400_hem2025000712C25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ajh.27576","article-title":"Hyper-CVAD and sequential blinatumomab without and with inotuzumab in young adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"100","author":"Kantarjian","year":"2025","journal-title":"Am J Hematol"},{"issue":"8","key":"2025120616325978400_hem2025000712C26","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2025120616325978400_hem2025000712C27","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.21.01693","article-title":"Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-Cell acute lymphoblastic leukemia: Children's Oncology Group Protocol AALL1621","volume":"40","author":"O'Brien","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025120616325978400_hem2025000712C28","first-page":"3918","article-title":"Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1","volume":"109","author":"Guest","year":"2024","journal-title":"Haematologica"},{"issue":"8","key":"2025120616325978400_hem2025000712C29","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J Clin Oncol"},{"issue":"36","key":"2025120616325978400_hem2025000712C30","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome- positive ALL","volume":"42","author":"Kantarjian","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025120616325978400_hem2025000712C31","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood-2006-08-040436","article-title":"Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"2025120616325978400_hem2025000712C32","article-title":"Addition of blinatumomab to consolidation therapy for younger adults (BCR::ABL1-negative B-acute lymphoblastic leukemia (ALL) on the ECOG-ACRIN E1910 phase III trial","author":"Dinner","year":"2025"},{"issue":"1","key":"2025120616325978400_hem2025000712C33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10555-020-09848-z","article-title":"Involvement of the central nervous system in acute lymphoblastic leukemia: opinions on molecular mechanisms and clinical implications based on recent data","volume":"39","author":"Lenk","year":"2020","journal-title":"Cancer Metastasis Rev"},{"issue":"25","key":"2025120616325978400_hem2025000712C34","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 Protocol: results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025120616325978400_hem2025000712C35","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","article-title":"Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial","volume":"36","author":"Pennesi","year":"2022","journal-title":"Leukemia"},{"key":"2025120616325978400_hem2025000712C36","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.1200\/JCO.2023.41.16_suppl.10016","article-title":"A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: second safety phase results from Children's Oncology Group AALL1732","volume":"41","author":"O'Brien","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025120616325978400_hem2025000712C37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ajh.25394","article-title":"Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin","volume":"94","author":"Jabbour","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"2025120616325978400_hem2025000712C38","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/cncr.33321","article-title":"Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed\/refractory acute lymphoblastic leukemia","volume":"127","author":"Stock","year":"2021","journal-title":"Cancer"},{"issue":"12","key":"2025120616325978400_hem2025000712C39","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1182\/bloodadvances.2023012430","article-title":"Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed\/refractory ALL","volume":"8","author":"Zhao","year":"2024","journal-title":"Blood Adv"},{"issue":"16","key":"2025120616325978400_hem2025000712C40","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"15","key":"2025120616325978400_hem2025000712C41","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1200\/JCO.2016.34.15_suppl.3011","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J Clin Oncol"},{"issue":"14","key":"2025120616325978400_hem2025000712C42","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy","volume":"139","author":"Leahy","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025120616325978400_hem2025000712C43","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/bloodadvances.2018018093","article-title":"Spontaneous reversion of a lineage switch following an initial blinatumomab- induced ALL-to-AML switch in MLL-rearranged infant ALL","volume":"2","author":"W\u00f6lfl","year":"2018","journal-title":"Blood Adv"},{"issue":"7","key":"2025120616325978400_hem2025000712C44","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1080\/10428194.2018.1562185","article-title":"Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A- rearranged acute lymphoblastic leukemia: a case report and review of the literature","volume":"60","author":"Fournier","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2025120616325978400_hem2025000712C45","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26594","article-title":"Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement","volume":"64","author":"Zoghbi","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2025120616325978400_hem2025000712C46","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/blood.2024026655","article-title":"Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia","volume":"146","author":"Silbert","year":"2025","journal-title":"Blood"},{"issue":"47","key":"2025120616325978400_hem2025000712C47","doi-asserted-by":"crossref","first-page":"76902","DOI":"10.18632\/oncotarget.12357","article-title":"T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts","volume":"7","author":"Feucht","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"2025120616325978400_hem2025000712C48","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven subtypes of B- progenitor acute lymphoblastic leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat Genet"},{"key":"2025120616325978400_hem2025000712C49","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2019-124881","article-title":"The genomic landscape of childhood acute lymphoblastic leukemia","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2025120616325978400_hem2025000712C50","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia","volume":"54","author":"Brady","year":"2022","journal-title":"Nat Genet"},{"issue":"29","key":"2025120616325978400_hem2025000712C51","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.23.02238","article-title":"Genomic determinants of outcome in acute lymphoblastic leukemia","volume":"42","author":"Chen","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025120616325978400_hem2025000712C52","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1038\/s41375-024-02329-0","article-title":"Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction","volume":"38","author":"Moorman","year":"2024","journal-title":"Leukemia"},{"key":"2025120616325978400_hem2025000712C53","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add6403","article-title":"PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia","author":"Li","year":"2022","journal-title":"Sci Adv"},{"issue":"11","key":"2025120616325978400_hem2025000712C54","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/leu.2015.134","article-title":"IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951","volume":"29","author":"Clappier","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"2025120616325978400_hem2025000712C55","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3324\/haematol.2011.056135","article-title":"IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol","volume":"98","author":"D\u00f6rge","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"2025120616325978400_hem2025000712C56","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"2025120616325978400_hem2025000712C57","doi-asserted-by":"crossref","first-page":"e875","DOI":"10.1097\/HS9.0000000000000875","article-title":"The prognostic effect of IKZF1 deletions in ETV6::RUNX1 and high hyperdiploid childhood acute lymphoblastic leukemia","volume":"7","author":"\u00d8stergaard","year":"2023","journal-title":"Hemasphere"},{"issue":"7","key":"2025120616325978400_hem2025000712C58","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1038\/s41375-025-02633-3","article-title":"Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia","volume":"39","author":"Wangondu","year":"2025","journal-title":"Leukemia"},{"issue":"11","key":"2025120616325978400_hem2025000712C59","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2013-06-509794","article-title":"IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL","volume":"123","author":"van der Veer","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2025120616325978400_hem2025000712C60","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"36","author":"Stanulla","year":"2018","journal-title":"J Clin Oncol"},{"issue":"25","key":"2025120616325978400_hem2025000712C61","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1200\/JCO.22.02705","article-title":"Improved outcome for ALL by prolonging therapy for IKZF1 deletion and decreasing therapy for other risk groups","volume":"41","author":"Pieters","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025120616325978400_hem2025000712C62","doi-asserted-by":"crossref","first-page":"e30313","DOI":"10.1002\/pbc.30313","article-title":"The prognostic value of IKZF1plus in B-cell progenitor acute lymphoblastic leukemia: results from the EORTC 58951 trial","volume":"70","author":"Kicinski","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2025120616325978400_hem2025000712C63","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hon.2973","article-title":"Prognostic significance of IKZF1 deletions and IKZF1plus profile in children with B-cell precursor acute lymphoblastic leukemia treated according to the ALL-IC BFM 2009 protocol","volume":"40","author":"Braun","year":"2022","journal-title":"Hematol Oncol"},{"issue":"1","key":"2025120616325978400_hem2025000712C64","doi-asserted-by":"crossref","first-page":"100060","DOI":"10.1016\/j.bneo.2024.100060","article-title":"Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL","volume":"2","author":"Cox","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"1","key":"2025120616325978400_hem2025000712C65","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1038\/s41467-025-58868-2","article-title":"IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies","volume":"16","author":"Domizi","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"2025120616325978400_hem2025000712C66","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2024023930","article-title":"Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL","volume":"144","author":"Zhao","year":"2024","journal-title":"Blood"},{"key":"2025120616325978400_hem2025000712C67","doi-asserted-by":"crossref","first-page":"e2400788","DOI":"10.1200\/PO-24-00788","article-title":"Challenging conventional diagnostic methods by comprehensive molecular diagnostics: a nationwide prospective comparison in children with ALL","volume":"9","author":"Boer","year":"2025","journal-title":"JCO Precis Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/252\/2470528\/252wangaondu.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/252\/2470528\/252wangaondu.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:33:07Z","timestamp":1765056787000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/252\/556900\/Revisiting-novel-genomic-classifiers-in-the-era-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000712","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}